Indole compounds for use in treating inflammation and cancer
US-9597316-B2 · Mar 21, 2017 · US
US9938246B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9938246-B2 |
| Application number | US-201615282312-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 30, 2016 |
| Priority date | Mar 31, 2014 |
| Publication date | Apr 10, 2018 |
| Grant date | Apr 10, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to disubstituted triazoles, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I) are provided.
Opening claim text (preview).
What is claimed is: 1. A compound, the compound of Formula (I): wherein: R 1 , R 5 and R 6 are hydrogen and R 2 , R 3 , and R 4 are independently chosen from hydrogen, methoxy, and hydroxyl, with the proviso that at least two of R 2 , R 3 , and R 4 are methoxy; and Ar is an aryl or substituted aryl group. 2. The compound of claim 1 , wherein Ar is chosen from phenyl, benzyl, substituted benzyl, benzoyl, substituted benzoyl, naphthyl, substituted naphthyl, naphthoyl, substituted naphthoyl, benzenesulphonyl, substituted benzenesulphonyl, heteroaryl; substituted heteroaryl, aroyl, heteroaroyl. 3. The compound of claim 1 , wherein the compound is Formula (I)(a): 4. The compound of claim 1 , wherein the compound is Formula (I)(b): 5. The compound of claim 1 , wherein the compound is Formula (I)(c): 6. The compound of claim 1 , wherein the compound is Formula (I)(d): 7. The compound of claim 1 , wherein the compound is Formula (I)(e): 8. The compound of claim 1 , wherein the compound is Formula (I)(f): 9. A pharmaceutical composition comprising a compound of Formula (I): wherein: R 1 , R 5 , and R 6 are hydrogen and R 2 , R 3 , and R 4 are independently chosen from hydrogen, methoxy, and hydroxyl, with the proviso that at least two of R 2 , R 3 , and R 4 are methoxy; and Ar is an aryl or substituted aryl group. 10. The pharmaceutical composition of claim 9 , wherein the compound of Formula (I) is selected from the group comprising Formula (I)(a), (I)(b), (I)(c), (I)(d), (I)(e), and (I)(f). 11. A compound, the compound selected from the group consisting of:
Antineoplastic agents · CPC title
with aryl radicals directly attached to ring atoms · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.